RMTI

Business Context and Reporting Period

Company: Rockwell Medical, Inc. (RMTI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Rockwell Medical develops, manufactures, and distributes hemodialysis products, primarily liquid and dry acid and bicarbonate concentrates, to dialysis providers in the U.S. and internationally. The Company operates in a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 8% to $17.3 million. This was primarily driven by a $3.9 million reduction in sales to DaVita, Inc., partially offset by $2.6 million in price increases and new customer sales. The prior year included a one-time $0.9 million price adjustment from DaVita that did not repeat.
• Cost of Sales: Decreased 9% to $14.4 million due to lower manufacturing costs from reduced headcount and overhead, offset by the loss of the DaVita price adjustment revenue.
• Operating Expenses: Selling and Marketing expenses decreased 20% due to lower headcount. General and Administrative expenses increased 3% due to higher compensation costs.
• Cash Flow Improvement: Net cash used in operating activities improved significantly from $3.5 million in Q1 2025 to $0.2 million in Q1 2026, driven by favorable changes in working capital accounts.
• Lease Obligations: The Company extended its Texas facility lease in January 2026, recognizing a new right-of-use asset and corresponding liability of approximately $2.5 million.

Guidance, Outlook, and Risks

• Liquidity: Management believes current working capital ($27.1 million) and cash resources ($23.9 million including investments) are sufficient to meet operating requirements for at least the next 12 months.
• Capital Resources: The Company has $13.1 million remaining availability under its At-The-Market (ATM) equity facility. Additional debt financing is restricted by a Securities Purchase Agreement with DaVita until DaVita's ownership stake falls below 50% of its original investment.
• Debt Covenants: The Company is in compliance with all covenants under its Loan Agreement with Innovatus Life Sciences. The loan is currently in an interest-only period through January 2027, with maturity extended to January 2029.
• Customer Concentration: Fresenius and Nipro each represented approximately 10-11% of revenue in Q1 2026. DaVita represented 7% of revenue in Q1 2026, down from 27% in Q1 2025, following a contract extension through December 2026.
• Risks: Risks include global macroeconomic instability, supply chain weaknesses, and the potential inability to raise additional capital on favorable terms if operational plans are not executed successfully.

Investor Verification Checklist

• DaVita Contract Status: Verify the stability of the relationship with DaVita, which recently extended its contract but previously indicated a potential transition to another supplier.
• Debt Maturity Profile: Review the $8.9 million term loan maturity schedule, noting the interest-only period ends in early 2027 and principal payments begin thereafter.
• ATM Facility Usage: Monitor the utilization of the remaining $13.1 million ATM facility and any potential dilution from future equity raises.
• Working Capital Trends: Assess the sustainability of the improved operating cash flow, which was heavily influenced by changes in accounts payable and receivable.
• Lease Commitments: Confirm the impact of the new Texas lease extension on future fixed costs and cash flow requirements.